Buried Techniques To MK0683

A pharmacological modulation of such mediators may contribute to reduce the impact of allostatic load, promoting resilience and better biochemical and neurocognitive performance translated as a better QOL. This study is based on the hypothesis that high potency benzodiazepines such as alprazolam may serve as more than single anxiety suppressive agents reducing allostatic load and facilitating adaptative responses. GEMA project proposes an intervention designed to determine if minimum doses of alprazolam adjust neurobiochemical mediators, neurocognition and affect QOL, altered by stress (MK0683 clinical trial Figure 2). Figure?2 Upper panel: Repeated stress (S-blue) conditions plus accumulation of allostatic loads (AL-red) result in chronic stress, and with time loss of the individual resilience (R-green) levels. Anxiety (A-yellow) emerges as a reaction of an excessive stress ... The question attempted to be solved is, whether anxiolytic pharmacology intervention with alprazolam in these high symptomatic patients modify allostatic load, neurocognition performance and QOL, beyond the known anxiolytic effect. Objectives (end points) The project consists of three complementary stages (figure 3). To determine whether clinical and biochemical markers of allostatic load tend to normalise with 12?weeks of therapeutic intervention. To determine if neurocognitive performance is modified after treatment, and if there is a positive correlation with biochemical variables of allostatic load and with therapeutic levels. To assess QOL before and after treatment. Figure?3 Stage I: Short-term evaluation of 0.75�C3.0?mg/day alprazolam on biochemical variables related to chronic stress. Stage II: Short-term evaluation of 0.75�C3.0?mg/day alprazolam on cognitive and clinical variables related ... Second, the purpose of this study is to report conditions of failure due to lack of response or emergence of undesired events, including adverse events, and possible situations of habituation to or dependence on alprazolam. Methods and analysis Protocol design The GEMA project, is a prospective phase IV clinical trial. The study began in 2010 and is still undergoing advanced trials. This is a prospective observational study, controlled with on-demand assignment of alprazolam doses in variable doses. It is a phase IV study reported to regulatory authorities in compliance with the rules in force and, consequently, enclosed for the use of experimental controls or interventions. The presence of variable doses will allow us to establish a continuous range of dose response.